Results 111 to 120 of about 30,059 (192)

Functional outcomes and toxicity following focal low-dose-rate brachytherapy for low-intermediate risk prostate cancer. [PDF]

BJUI Compass
Adhami M, Cheng J, Anderson E, Smyth L, Davey C, Nguyen T, O'Sullivan R, Ryan A, Lawrentschuk N, Grummet J, See A.   +10 more
europepmc   +1 more source

Dosimetric comparison of MRI-guided and CT-guided intracavitary and interstitial brachytherapy for locally advanced cervical cancer. [PDF]

Front Oncol
Yang W, Lu J, Wang L, Wang H, Li P, Zhang Q.   +5 more
europepmc   +1 more source

Supportive Care for HDR Brachytherapy in Gynecological Cancer: A Single Center Experience. [PDF]

In Vivo
Meinecke D, Bruns F, Christiansen H, Steinkasserer L, Knöchelmann AC.   +4 more
europepmc   +1 more source

Balancing Efficacy and Toxicity in Salvage Brachytherapy and SBRT for Radio-Recurrent Prostate Cancer: Insights Beyond the UroGEC Review. [PDF]

Technol Cancer Res Treat
Bilski M, Fijuth J, Kuncman Ł.
europepmc   +1 more source

A Novel Three-Dimension Printed Individualized Curved-Needle-Based Interstitial Brachytherapy for Re-Irradiation in Uterine Fundus-Involving Recurrent Cervical Cancer: A Case Report. [PDF]

Curr Oncol
Zhang Y, Zhang J, Zhong M, Yu L, Luo C, Yan J, Hu K.   +6 more
europepmc   +1 more source

3D transformer-based dose prediction in HDR brachytherapy for cervical cancer. [PDF]

BMC Cancer
Guo W, Jian W, Zhu L, Zhang B, He Q, Yang G, Wang X.   +6 more
europepmc   +1 more source

Impact of rectal gas evacuation on dosimetry and applicator displacement in cervical cancer brachytherapy. [PDF]

J Appl Clin Med Phys
Wu H, He C, Liu M, Zhao X.
europepmc   +1 more source

Case reports that high-dose-rate brachytherapy using custom-designed mouthpiece mold for early-stage squamous cell carcinoma of the hard palate is useful. [PDF]

Radiat Oncol
Yoshino Y, Masui K, Takenaka T, Kawabata K, Aibe N, Kimoto T, Nagasawa S, Kajikawa T, Ikeda S, Kawamoto T, Oseko F, Yamazaki H, Yamada K, Suzuki G.   +13 more
europepmc   +1 more source

Oncological outcomes post focal low-dose-rate brachytherapy in low-intermediate risk prostate cancer. [PDF]

BJUI Compass
Adhami M, Cheng J, Anderson E, Smyth L, Davey C, Nguyen T, O'Sullivan R, Ryan A, Lawrentschuk N, Grummet J, See A.   +10 more
europepmc   +1 more source

Retrospective evaluation of high-dose-rate brachytherapy multicriteria planning using physical dose versus radiobiological criteria for prostate cancer. [PDF]

Sci Rep
Iorio-Duval C, Bélanger C, Vigneault É, Beaulieu L.   +3 more
europepmc   +1 more source